WITHUS PHARMACEUTICAL Co.,LTD. (KOSDAQ:330350)
South Korea
· Delayed Price · Currency is KRW 5,960.00
-130.00 (-2.13%)
At close: Mar 28, 2025, 3:30 PM KST
KOSDAQ:330350 Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 102,722 | 80,119 | 64,680 | 57,419 | 53,406 | Upgrade
|
| Other Revenue | - | -0 | - | - | -0 | Upgrade
|
| Revenue | 102,722 | 80,119 | 64,680 | 57,419 | 53,406 | Upgrade
|
| Revenue Growth (YoY) | 28.21% | 23.87% | 12.65% | 7.51% | 1.93% | Upgrade
|
| Cost of Revenue | 37,168 | 31,481 | 26,345 | 23,894 | 21,076 | Upgrade
|
| Gross Profit | 65,554 | 48,638 | 38,335 | 33,525 | 32,330 | Upgrade
|
| Selling, General & Admin | 56,002 | 37,237 | 29,767 | 26,100 | 22,699 | Upgrade
|
| Research & Development | 2,297 | 1,868 | 2,357 | 1,420 | 1,807 | Upgrade
|
| Other Operating Expenses | 178.61 | 186.67 | 278.07 | 296.44 | 202.68 | Upgrade
|
| Operating Expenses | 59,893 | 40,729 | 33,457 | 28,639 | 25,100 | Upgrade
|
| Operating Income | 5,661 | 7,909 | 4,878 | 4,886 | 7,230 | Upgrade
|
| Interest Expense | -814.08 | -596.06 | -390.74 | -323.96 | -229.23 | Upgrade
|
| Interest & Investment Income | 486.88 | 727.19 | 468.62 | 392.66 | 464.09 | Upgrade
|
| Currency Exchange Gain (Loss) | -3.18 | 1.72 | 0.63 | -3.98 | 6.57 | Upgrade
|
| Other Non Operating Income (Expenses) | 147.77 | -425.51 | -435.03 | -305.14 | -235.98 | Upgrade
|
| EBT Excluding Unusual Items | 5,478 | 7,617 | 4,521 | 4,646 | 7,236 | Upgrade
|
| Gain (Loss) on Sale of Investments | -133.97 | 1,515 | -373.86 | 979.32 | 520.11 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 9.04 | 10.78 | -385 | 5.13 | Upgrade
|
| Asset Writedown | -205 | - | - | - | - | Upgrade
|
| Pretax Income | 5,139 | 9,141 | 4,158 | 5,240 | 7,761 | Upgrade
|
| Income Tax Expense | 354.3 | 1,182 | 1,679 | 976.07 | 1,109 | Upgrade
|
| Net Income | 4,785 | 7,959 | 2,479 | 4,264 | 6,652 | Upgrade
|
| Net Income to Common | 4,785 | 7,959 | 2,479 | 4,264 | 6,652 | Upgrade
|
| Net Income Growth | -39.88% | 221.04% | -41.86% | -35.91% | -17.24% | Upgrade
|
| Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 8 | Upgrade
|
| Shares Change (YoY) | 0.14% | 0.08% | -0.09% | 59.55% | 6.63% | Upgrade
|
| EPS (Basic) | 362.00 | 603.00 | 187.97 | 323.00 | 804.02 | Upgrade
|
| EPS (Diluted) | 362.00 | 603.00 | 187.97 | 323.00 | 804.02 | Upgrade
|
| EPS Growth | -39.97% | 220.80% | -41.81% | -59.83% | -22.39% | Upgrade
|
| Free Cash Flow | 7,268 | -12,044 | -9,952 | 1,354 | -4,455 | Upgrade
|
| Free Cash Flow Per Share | 549.86 | -912.45 | -754.57 | 102.59 | -538.39 | Upgrade
|
| Gross Margin | 63.82% | 60.71% | 59.27% | 58.39% | 60.54% | Upgrade
|
| Operating Margin | 5.51% | 9.87% | 7.54% | 8.51% | 13.54% | Upgrade
|
| Profit Margin | 4.66% | 9.93% | 3.83% | 7.43% | 12.46% | Upgrade
|
| Free Cash Flow Margin | 7.07% | -15.03% | -15.39% | 2.36% | -8.34% | Upgrade
|
| EBITDA | 9,438 | 10,754 | 6,826 | 6,387 | 9,207 | Upgrade
|
| EBITDA Margin | 9.19% | 13.42% | 10.55% | 11.12% | 17.24% | Upgrade
|
| D&A For EBITDA | 3,778 | 2,844 | 1,948 | 1,501 | 1,977 | Upgrade
|
| EBIT | 5,661 | 7,909 | 4,878 | 4,886 | 7,230 | Upgrade
|
| EBIT Margin | 5.51% | 9.87% | 7.54% | 8.51% | 13.54% | Upgrade
|
| Effective Tax Rate | 6.89% | 12.93% | 40.38% | 18.63% | 14.29% | Upgrade
|
| Advertising Expenses | 832.52 | 841.87 | 831.45 | 887 | - | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.